Branded GLP-1 and oral weight-loss medication comparison

Wegovy vs Contrave: weekly semaglutide injection or oral naltrexone/bupropion?

Compare Wegovy and Contrave by label fit, injection versus oral routine, GLP-1 safety questions, mental-health, opioid, seizure, blood-pressure, cost, and online clinic red flags.

Educational guideUpdated June 15, 2026

Safe Wegovy vs Contrave comparison path

1

Name the exact option first: Wegovy, Ozempic, Rybelsus, compounded semaglutide, Contrave, separate naltrexone/bupropion, or another clinician-reviewed medicine.

2

Match the goal to the label context: chronic weight management, cardiovascular-risk reduction, type 2 diabetes coordination, appetite or cravings support, maintenance, or another prescriber-reviewed reason.

3

Screen safety before price: thyroid tumor warning history, pancreatitis or gallbladder disease, severe GI symptoms, dehydration risk, seizure history, eating-disorder history, mood changes, suicidal thoughts, opioid use, blood pressure, kidney or liver disease, and pregnancy plans can change the recommendation.

4

Compare the routine honestly: weekly injection logistics, storage, refill timing, and GLP-1 side-effect support for Wegovy versus twice-daily oral extended-release tablets, mental-health monitoring, opioid-blocking implications, and blood-pressure follow-up for Contrave.

5

Avoid no-prescription semaglutide sellers, research-use GLP-1 products, “generic Wegovy” claims, Contrave-like ingredient stacks, opioid-blocker surprises, bupropion dose shortcuts, and guaranteed weight-loss advertising.

Direct answer

Wegovy and Contrave are both prescription chronic weight-management medicines for eligible patients, but they are not interchangeable. Wegovy contains semaglutide, a weekly GLP-1 receptor agonist injection. Contrave is an oral extended-release tablet that combines naltrexone and bupropion. A licensed clinician should compare diagnosis, weight-related conditions, cardiovascular-risk context, gastrointestinal tolerance, thyroid tumor warning history, pancreatitis or gallbladder history, kidney risk from dehydration, mental-health history, seizure risk, opioid use, blood pressure, pregnancy plans, medication interactions, cost, pharmacy access, and follow-up before recommending either pathway.

Mechanism and label fit

What is the main difference between Wegovy and Contrave?

Wegovy is a branded semaglutide injection used in chronic weight-management care and selected risk-reduction contexts. Contrave is a fixed-dose oral extended-release medicine containing naltrexone, an opioid antagonist, and bupropion, an antidepressant also used in other products. The comparison should start with the exact product, diagnosis, and medication list because Wegovy, Ozempic, Rybelsus, compounded semaglutide, Contrave, and separate naltrexone or bupropion prescriptions have different label contexts, warnings, contraindication questions, pharmacy issues, and follow-up needs.

  • Wegovy review commonly focuses on GLP-1 product identity, chronic weight-management criteria, cardiovascular-risk context when relevant, thyroid tumor warning history, pancreatitis or gallbladder history, severe nausea, vomiting, diarrhea, dehydration-related kidney risk, diabetes medicines, pregnancy plans, and pharmacy access.
  • Contrave review commonly focuses on mood or suicidal-thought warnings, seizure risk, eating-disorder history, uncontrolled blood pressure, opioid use or opioid-use-disorder treatment, abrupt alcohol or sedative changes, liver or kidney disease, pregnancy plans, and interacting antidepressants or MAOIs.
  • Compounded semaglutide may be discussed separately when clinically and legally appropriate for an individualized prescription, but compounded preparations are not FDA-approved finished drug products or generic Wegovy.

Choosing a care path

Which patients may be steered toward one discussion over the other?

A clinician may discuss Wegovy when a patient’s records, weight-related conditions, cardiometabolic context, prior GLP-1 response, side-effect history, and follow-up capacity fit a semaglutide pathway. Contrave may come up when an oral weight-management medication is being considered and opioid, seizure, psychiatric, blood-pressure, kidney, liver, and interaction risks can be reviewed safely. The decision should also consider affordability, insurance rules, pharmacy availability, pregnancy potential, and the patient’s ability to complete check-ins.

  • Wegovy may be a better discussion when weekly GLP-1 weight-management care fits the diagnosis and the patient can manage injection logistics, storage questions, refill timing, gastrointestinal side-effect support, nutrition planning, and follow-up.
  • Contrave may be inappropriate or require extra caution for patients with seizure disorders, current or past bulimia or anorexia, uncontrolled hypertension, chronic opioid therapy, opioid-use-disorder treatment, recent opioid exposure, certain psychiatric histories, abrupt alcohol or sedative changes, or recent MAOI use.
  • Patients should ask who coordinates primary care, cardiology or diabetes context, mental-health care, pain management, blood-pressure monitoring, pregnancy-safety counseling, nutrition, side effects, refills, and stopping-plan questions.

Switching and combination questions

Do not self-combine Wegovy and Contrave from online stack advice

Online forums sometimes frame Wegovy, compounded semaglutide, Contrave, separate naltrexone and bupropion prescriptions, phentermine, topiramate, or tirzepatide products as mix-and-match weight-loss stacks. That is unsafe without a coordinated prescriber. Combining or switching therapies can change nausea, hydration, appetite, glucose trends, dizziness, sleep, blood pressure, mood symptoms, seizure risk, opioid pain-control options, and recognition of urgent symptoms. A safe plan needs one accountable clinician or a clearly coordinated care team.

  • Ask whether A1C or glucose history, kidney function, gallbladder symptoms, blood pressure, seizure history, eating-disorder history, alcohol use, opioid exposure, mood history, pregnancy plans, cardiovascular history, and current medicines should be reviewed before a change.
  • Tell the clinician about insulin, sulfonylureas, opioid pain medicines, tramadol, buprenorphine, methadone, antidepressants, stimulants, seizure medicines, migraine medicines, blood-pressure medicines, sleep medicines, alcohol use, and supplements.
  • Avoid sellers that provide semaglutide vial math, Contrave-like ingredient stacks, opioid-blocker advice, bupropion dose shortcuts, no-prescription checkout, research-use GLP-1 products, guaranteed results, or instructions to stop psychiatric, pain, seizure, diabetes, or heart care without the managing clinician.

Online clinic quality

How should patients compare online clinics for these options?

A responsible online clinic should name the exact medication pathway, explain why it fits the patient’s diagnosis and risks, distinguish FDA-approved branded products from individualized compounded prescriptions, use legitimate pharmacy channels, and provide follow-up. A low advertised monthly price may be misleading if it excludes clinician review, records or lab review when relevant, injection supplies, shipping, side-effect support, mental-health or blood-pressure monitoring, refill reassessment, insurance paperwork, or cancellation terms.

  • Ask whether the quote includes intake, clinician review, medication, pharmacy dispensing, injection supplies when needed, shipping, refills, side-effect support, medication-list reconciliation, and coordination with primary care, mental health, pain management, endocrinology, cardiology, or OB-GYN when needed.
  • Ask whether compounded semaglutide is clearly described as not an FDA-approved finished drug product and whether pharmacy labels include active ingredient, route, strength or concentration, storage, and beyond-use date or expiration.
  • Be cautious with no-prescription peptide sellers, research-use semaglutide, “generic Wegovy” or “generic Ozempic” claims, unbundled naltrexone/bupropion stacks sold as shortcuts, guaranteed results, or pressure to buy bundles before clinician review.

Patient safety checklist

Questions to ask before choosing Wegovy or Contrave online

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

What exact medicine is being recommended: Wegovy, Ozempic, Rybelsus, compounded semaglutide, Contrave, separate naltrexone and bupropion, or another option?

✓

Is my goal chronic weight management, cardiovascular-risk reduction, type 2 diabetes coordination, appetite or cravings support, weight-regain prevention, or another clinician-reviewed reason?

✓

Does the labeled-use pathway match my records, weight-related conditions, cardiometabolic context, current medicines, and follow-up plan?

✓

Have thyroid cancer or MEN2 history, pancreatitis or gallbladder disease, kidney disease, severe GI symptoms, seizure history, eating-disorder history, mood changes, suicidal thoughts, uncontrolled blood pressure, opioid use, alcohol or sedative changes, pregnancy plans, and breastfeeding questions been reviewed?

✓

Am I using insulin, sulfonylureas, opioids, tramadol, buprenorphine, methadone, antidepressants, stimulants, MAOIs, seizure medicines, migraine medicines, blood-pressure medicines, sleep medicines, alcohol, or supplements that should be coordinated?

✓

If compounded semaglutide is discussed, does the clinic clearly state that compounded semaglutide is not an FDA-approved finished drug product?

✓

If Contrave is discussed, who explains mood-warning monitoring, seizure-risk screening, opioid-blocking implications, blood-pressure checks, treatment-response reassessment, and when care should stop or change?

✓

Does the seller avoid guaranteed weight-loss claims, no-prescription products, research-use vials, generic dosing charts, and pressure to buy bundles before clinician review?

FAQs

Short answers for patients

Is Wegovy the same as Contrave?

No. Wegovy contains semaglutide, a weekly GLP-1 receptor agonist injection. Contrave is an oral extended-release tablet containing naltrexone and bupropion. They have different mechanisms, warnings, contraindication questions, side effects, routes, pharmacy issues, and follow-up needs.

Which works better for weight loss, Wegovy or Contrave?

There is no universal better option. Wegovy and Contrave have different evidence bases, labels, routes, contraindications, and monitoring needs. The right discussion depends on diagnosis, weight-related conditions, cardiovascular or diabetes context, mental-health history, seizure risk, opioid use, blood pressure, other medicines, cost, pharmacy access, and prescriber judgment.

Can Wegovy and Contrave be taken together?

Do not combine weight-management medicines unless the same licensed clinician reviews the full plan or coordinates with the clinicians managing related medicines. Combining options can change nausea, hydration, glucose readings, dizziness, mood symptoms, sleep, blood pressure, seizure risk, opioid pain-control planning, and side-effect monitoring.

Is compounded semaglutide FDA-approved like Wegovy?

No. Wegovy, Ozempic, and Rybelsus are FDA-approved brand-name semaglutide products for specific labeled uses. Compounded semaglutide may be considered only under an individualized prescription when clinically and legally appropriate, but compounded preparations are not FDA-approved finished drug products or generic Wegovy.

Who should be cautious with Contrave?

Patients should disclose seizure history, eating-disorder history, mood changes or suicidal thoughts, uncontrolled high blood pressure, opioid use or recent opioid exposure, opioid-use-disorder treatment, alcohol or sedative use changes, liver or kidney disease, pregnancy plans, breastfeeding questions, and all psychiatric, pain, sleep, stimulant, migraine, and seizure medicines.

How should cost be compared?

Compare the full care model, not only a monthly drug price. Ask whether the price includes intake, clinician review, medication, pharmacy dispensing, injection supplies when needed, shipping, records or labs when relevant, side-effect support, mental-health or blood-pressure monitoring, refill reassessment, insurance support, cancellation rules, and branded versus compounded access.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Wegovy (semaglutide) prescribing informationMedlinePlus: Semaglutide injectionDailyMed: Contrave (naltrexone hydrochloride and bupropion hydrochloride) prescribing informationMedlinePlus: Naltrexone and bupropionFDA: FDA's concerns with unapproved GLP-1 drugs used for weight lossFDA: Compounding and the FDA questions and answersPeptide12: WegovyPeptide12: Compounded semaglutide injectionPeptide12: Semaglutide vs ContravePeptide12: Zepbound vs ContravePeptide12: Wegovy vs QsymiaPeptide12: Wegovy vs ZepboundPeptide12: Wegovy vs OzempicPeptide12: Semaglutide vs phenterminePeptide12: Semaglutide vs topiramatePeptide12: GLP-1 glucose monitoring questionsPeptide12: Mental health history reviewPeptide12: Eating disorder history reviewPeptide12: Blood pressure medication questionsPeptide12: How online peptide therapy works